Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing.

Clinical pharmacology and therapeutics - 1 Apr 2016

Gammal R S, Court M H, Haidar C E, Iwuchukwu O F, Gaur A H, Alvarellos M, Guillemette C, Lennox J L, Whirl-Carrillo M, Brummel S S, Ratain M J, Klein T E, Schackman B R, Caudle K E, Haas D W

Abstract excerpt

The antiretroviral protease inhibitor atazanavir inhibits hepatic uridine diphosphate glucuronosyltransferase (UGT) 1A1, thereby preventing the glucuronidation and elimination of bilirubin. Resultant indirect hyperbilirubinemia with jaundice can cause premature discontinuation of atazanavir. Risk for bilirubin-related discontinuation is highest among individuals who carry two UGT1A1 decreased function alleles...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Glucuronosyltransferase
Share to HIV Protease Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hyperbilirubinemia

Share to Jaundice

Share to Pharmacogenetics

Share to Risk Assessment

Share to Risk Factors

Source

Open in PubMed Open full text

Identifiers

PMID: 26417955
DOI: 10.1002/cpt.269
PMCID: PMC4785051

Genes

UGT1A1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing.PMID 26417955Read ↗

Effect of the UGT1A1*28 allele on unconjugated hyperbilirubinemia in HIV-positive patients receiving Atazanavir: a systematic review.Semantic proximity Read ↗

Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 update.Semantic proximity Read ↗

Pharmacogenetics of Gilbert's syndrome.Semantic proximity Read ↗

Gilbert's disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype.Semantic proximity Read ↗

Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz‐Containing Antiretroviral TherapySemantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz‐Containing Antiretroviral TherapySemantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole TherapySemantic proximity Read ↗

Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study).Semantic proximity Read ↗

The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.